X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/22/2850942/36989/en/Checkpoint-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com/news-release/2024/03/18/2847762/36989/en/Checkpoint-Therapeutics-Announces-Appointment-of-Accomplished-Life-Sciences-Executive-Amit-Sharma-M-D-to-Board-of-Directors.html
https://www.globenewswire.com/news-release/2024/01/29/2818873/36989/en/Checkpoint-Therapeutics-Announces-14-Million-Registered-Direct-Offering-Priced-At-the-Market.html
https://www.globenewswire.com//news-release/2024/01/11/2807906/36989/en/Checkpoint-Therapeutics-to-Participate-in-the-B-Riley-Securities-4th-Annual-Oncology-Conference.html
https://www.nasdaq.com/articles/us-fda-declines-to-approve-checkpoint-therapeutics-skin-cancer-therapy
https://www.globenewswire.com/news-release/2023/12/05/2790924/36989/en/Checkpoint-Therapeutics-Strengthens-Intellectual-Property-Protection-for-Cosibelimab-with-New-U-S-Patent-Issuance.html
https://www.globenewswire.com//news-release/2023/11/13/2779566/36989/en/Checkpoint-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html
https://www.globenewswire.com//news-release/2023/10/18/2762378/36989/en/Checkpoint-Therapeutics-Announces-Publication-of-Cosibelimab-Pivotal-Trial-Results-in-the-Journal-for-ImmunoTherapy-of-Cancer.html
https://www.globenewswire.com//news-release/2023/10/16/2760538/0/en/Beyond-Cancer-Presents-Positive-Preclinical-Data-for-Ultra-High-Concentration-Nitric-Oxide-UNO-in-Combination-with-Checkpoint-Inhibitor-Therapy-During-the-2023-AACR-NCI-EORTC-Inter.html
https://www.globenewswire.com//news-release/2023/10/02/2753067/36989/en/Checkpoint-Therapeutics-Announces-Exercise-of-Warrants-for-11-13-Million-in-Gross-Proceeds.html
Market Place
Share 
